Stock Split History
ETFs Holding RPRX »    RPRX Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. According to our Royalty Pharma stock split history records, Royalty Pharma has had 0 splits.
Royalty Pharma stock split history picture
Royalty Pharma (RPRX) has 0 splits in our Royalty Pharma stock split history database.

Looking at the Royalty Pharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Royalty Pharma shares, starting with a $10,000 purchase of RPRX, presented on a split-history-adjusted basis factoring in the complete Royalty Pharma stock split history. Royalty Pharma split adjusted history picture

Growth of $10,000.00
With Dividends Reinvested

Start date: 06/16/2020
End date: 11/25/2022
Start price/share: $44.50
End price/share: $42.98
Starting shares: 224.72
Ending shares: 234.35
Dividends reinvested/share: $1.74
Total return: 0.72%
Average Annual Total Return: 0.30%
Starting investment: $10,000.00
Ending investment: $10,073.47
Years: 2.44
Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/16/2020
End date: 11/25/2022
Start price/share: $44.50
End price/share: $42.98
Dividends collected/share: $1.74
Total return: 0.49%
Average Annual Total Return: 0.20%
Starting investment: $10,000.00
Ending investment: $10,048.95
Years: 2.44
Date Ratio
Astrotech Corporation (ASTC)
SuperCom (SPCB)
Qualigen Therapeutics, Inc. (QLGN)
MicroSectors Oil & Gas Exploration & Production -3X Inverse Leveraged ETNs due June 28, 2041 (OILD)
MicroSectors U.S. Big Oil Index -3X Inverse Leveraged ETNs due March 25, 2039 (NRGD)
Ebang International Holdings Inc. (EBON)
Global X Blockchain ETF (BKCH)
Global X Blockchain & Bitcoin Strategy ETF (BITS)
Global X Emerging Markets Internet & E-commerce ETF (EWEB)
Global X MSCI China Real Estate ETF (CHIR)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Royalty Pharma

Royalty Pharma Stock Split History | | Copyright © 2013 - 2022, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.